摘要目的 观察复方甘草酸苷联合重组人表皮生长因子治疗湿疹的疗效.方法 120例慢性湿疹患者随机分为治疗组(60例)和对照组(60例),治疗组静脉注射复方甘草酸苷,60 ml/次,1次/d,联合重组人表皮生长因子喷撒患处,3次/d;对照组单纯给予静脉注射复方甘草酸苷,60 ml/次,1次/d;两组均连续治疗1个月后观察疗效和不良反应.结果 治疗组有效率91.67%,高于对照组的71.67%(x2=6.43,P＜0.05).治疗组VAS积分较对照组、同组治疗前后差异均有统计学意义(t=2.77、2.13、2.42,均P＜0.05).两组均无严重不良反应.结论 复方甘草酸苷联合重组人表皮生长因子治疗湿疹疗效显著,值得推广.

abstractsObjective To observe the effect and safety of the compound glycyrrhizin combined recombinant human epidermal growth factor in treatment of eczema. Methods 120 eczema patients were selected randomly divided into the treatment group (n=60) and the control group (n=60) ,the treatment group intravenously given compound glycyrrhizin once a day, 60ml combined recombinant human epidermal growth factor analgesic spray, three times a day. The control group were given intravenously compound glycyrrhizin,once a day ,60ml. Two groups of patients were continuous treatment after a month observation curative effect and adverse reaction. Results The effective rate in the treatment group(91. 67%) was higher than the control group(71.67%) ,there was significant difference(x2=6.43,P＜0.05). Compared with control group, VAS of the treatment group was significantly reduced, there is significant difference (P＜0.05). In the same group,within one month after treatment,before treatment and after treatment compared also has difference, there are significant difference (P＜0.05). The two groups had no serious adverse reactions. Conclusion Effect of compound glycyrrhizin combined recombinant human epidermal growth factor in treatment of eczema curative was distinct,which was worth extending.